Lyell Immunopharma (LYEL)
(Real Time Quote from BATS)
$1.45 USD
-0.04 (-2.69%)
Updated Aug 5, 2024 02:48 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LYEL 1.45 -0.04(-2.69%)
Will LYEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LYEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYEL
Lyell Immunopharma (LYEL) Is Up 28.45% in One Week: What You Should Know
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
LYEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
Corcept (CORT) Surges 5.1%: Is This an Indication of Further Gains?
Lyell Immunopharma (LYEL) Reports Q1 Loss, Lags Revenue Estimates
Other News for LYEL
What You Missed On Wall Street This Morning
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls
Lyell Immunopharma price target lowered by $3 at BofA, here's why
Hold Rating on Lyell Immunopharma Amid Safety Concerns and Efficacy Doubts for LYL797 Treatment
Lyell Immunopharma just downgraded at H.C. Wainwright, here's why